Shots:

• Numab to receive up front- research funding- success fees- milestones & royalties on sales. Eisai to get an option to acquire an exclusive license to develop and commercialize novel multi-specific antibody-based molecules developed utilizing Numab’s MATCH platform
• The focus of the agreement is to leverage Numab’s multi-specific technology to generate cancer therapies providing superior efficacy and safety as compared to benchmark immunotherapies
• Numab is utilizing its Fv-stabilizing λcap technology and MATCH platform to generate multi-specific Ab with a plug-and-play novel mechanism with superior efficacy and favorable safety profiles

Click here to­ read full press release/ article | Ref: Businesswire | Image: Twitter